problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl20115733-10problendo-4736Research ArticleСтатьиArticlesЭпидемиология первичного гиперпаратиреоза в России (первые результаты по базе данных ФГУ ЭНЦ)Epidemiology of primary hyperparathyroidism in Russia (the first results from the database of Federal state institution «Endocrinological Research Centre»)DedovI I-MokryshevaN G-MirnaiaS S-RostomianL G-PigarovaE A-RozhinskaiaL Ia-201115062011573ТОМ 57, №3 (2011)310Copyright © Dedov I.I., Mokrysheva N.G., Mirnaia S.S., Rostomian L.G., Pigarova E.A., Rozhinskaia L.I., 20112011Dedov I.I., Mokrysheva N.G., Mirnaia S.S., Rostomian L.G., Pigarova E.A., Rozhinskaia L.I.Dedov I.I., Mokrysheva N.G., Mirnaia S.S., Rostomian L.G., Pigarova E.A., Rozhinskaia L.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4736

Оценивали эпидемиологические особенности различных форм первичного гиперпаратиреоза (ПГПТ) в России на основе базы данных ФГУ ЭНЦ, включившей 561 пациента за 19 лет. Заболеваемость ПГПТ в Москве по обращаемости в ФГУ ЭНЦ на 2007 г. составила 6,8 на 1 млн взрослого населения, распространенность к 2009 г. достигает 3,1 на 100 тыс. человек, что значительно меньше зарубежных данных. Соотношение мужчин и женщин - 1:8, пик заболеваемости 50-60 лет. К 2004 г. частота выявления мягкой формы (по критериям Консенсуса 2002 г.) составляла не более 20% случаев. За последние 5 лет доля мягкой формы достигла 37%. Рекомендовать консервативное лечение (по критериям консенсуса 2008 г.) можно в 14% случаев спорадического ПГПТ и в 32% при МЭН синдроме. Частота бессимптомной формы ПГПТ - 5%, нормокальциемической формы - 9%. Полученные результаты являются первыми данными по вопросам эпидемиологии в России, но не позволяют оценить весь масштаб проблемы. Для адекватной оценки ситуации необходимо проведение крупных эпидемиологических исследований.

To elucidate specific features of epidemiology of various forms of primary hyperparathyroidism (PHPT) in this country using the information about 561 patients accumulated for 19 years in the database of Federal state institution «Endocrinological Research Centre». The incidence of PHPT in Moscow estimated from the database of Endocrinological Research Centre for 2007 was 6.8 per 1 000 000 adult population and the prevalence as per 2009 was 3.1/100 000. These values are significantly lower than those reported by foreign authors. The men to women ratio among the patients with PHPT was 1:8. The disease largely affects subjects at the age from 50 to 60 years. By the year of 2004, the frequency of the mild form of PHPT did not exceed 20% of the total (based on 2002 Consensus criteria). It increased to 37% during the past 5 years. Conservative treatment of PHPT can be recommended to 14% of the patients presenting with sporadic disease and to 32% of those with MEN syndrome. The frequency of asymptotic PHPT and its normocalcemic forms is estimated at 5% and 9% respectively. The above results are the first data on epidemiology of PHPT in this country; however, they are insufficient to comprehensively evaluate the real significance of the problem. Large-scale epidemiological studies are needed to ensure adequate assessment of the situation.

первичный гиперпаратиреозгиперкальциемияэпидемиологиясиндром МЭН 1-го типаprimary hyperparathyroidismhypercalcemiaepidemiologytype 1 MEN syndromeReferencesГолохвастов Н.Н., Эммануэль В.Л., Рыбакова Г.В., Мягков Л.В. Скрининг кальция крови стационарных больных для выявления первичного гиперпаратиреоза. Современные аспекты хирургической эндокринологии. Саранск 1997;82-85.Голохвастов Н.Н., Эммануэль В.Л., Рыбакова Г.В., Мягков Л.В. Скрининг кальция крови стационарных больных для выявления первичного гиперпаратиреоза. Современные аспекты хирургической эндокринологии. Саранск 1997;82-85.Marx S.J. Multiple endocrine neoplasia type 1. In: The metabolic and molecular bases of inherited disease, 8th ed. Eds. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle. New York 2001;943-966.Marx S.J. Multiple endocrine neoplasia type 1. In: The metabolic and molecular bases of inherited disease, 8th ed. Eds. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle. New York 2001;943-966.Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002;17:Suppl 2:N18-N23.Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002;17:Suppl 2:N18-N23.Flynn R.W., Macdonald T.M., Jung R.T. et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006;91:2159-2164.Flynn R.W., Macdonald T.M., Jung R.T. et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006;91:2159-2164.Morris A.D., Boyle D.I., MacAlpine R. et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. Br Med J 1997;315:524-528.Morris A.D., Boyle D.I., MacAlpine R. et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. Br Med J 1997;315:524-528.Котова И.В., Титова Н.В. Бессимптомный и нормокальциемический первичный гиперпаратиреоз (обзор литературы и собственные наблюдения). Пробл эндокринол и патол (Украина) 2003;1:8-12.Котова И.В., Титова Н.В. Бессимптомный и нормокальциемический первичный гиперпаратиреоз (обзор литературы и собственные наблюдения). Пробл эндокринол и патол (Украина) 2003;1:8-12.Печерская Г.А., Ишенин Ю.М. Диагностические аспекты первичного гиперпаратиреоза. Казан мед журн 2000;3:226-227.Печерская Г.А., Ишенин Ю.М. Диагностические аспекты первичного гиперпаратиреоза. Казан мед журн 2000;3:226-227.Bilezikian J.P., Potts J.T., Fuleihan G.E. et al. Summary statement from a workshop on asymptomatic primary hyperthyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353-5361.Bilezikian J.P., Potts J.T., Fuleihan G.E. et al. Summary statement from a workshop on asymptomatic primary hyperthyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353-5361.NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Int Med 1991;114:7:593-597.NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Int Med 1991;114:7:593-597.Jorde R., Bonaa K.H., Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso study. J Clin Epidemiol 2000;53:1164-1169.Jorde R., Bonaa K.H., Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso study. J Clin Epidemiol 2000;53:1164-1169.Wermers R.A., Atkinson E.J., Achenbach S.J. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:1:171-177.Wermers R.A., Atkinson E.J., Achenbach S.J. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:1:171-177.Yu N., Donnan P.T., Murphy M.J., Leese G.P. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf) 2009;71:4:485-493.Yu N., Donnan P.T., Murphy M.J., Leese G.P. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf) 2009;71:4:485-493.Blichert-Toft M., Mollerup C.L., Feldt-Rasmussen U.F. et al. Primary hyperparathyroidism. An underdiagnosed disease in Denmark. Ugeskr Laeger 1993;155:765-769.Blichert-Toft M., Mollerup C.L., Feldt-Rasmussen U.F. et al. Primary hyperparathyroidism. An underdiagnosed disease in Denmark. Ugeskr Laeger 1993;155:765-769.The Mattson Jack Group. Epidemiology of Primary Hyperparathyroidism in Europe - report commissioned by Amgen. Ref Type: Report 2003.The Mattson Jack Group. Epidemiology of Primary Hyperparathyroidism in Europe - report commissioned by Amgen. Ref Type: Report 2003.AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract 2005;11:1:49-54.AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract 2005;11:1:49-54.Richert L., Trombetti A., Herrmann F.R. et al. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swiss Med Wkly 2009;139:27-28:400-404.Richert L., Trombetti A., Herrmann F.R. et al. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swiss Med Wkly 2009;139:27-28:400-404.Weber T., Keller M., Hense I. et al. Effect of parathyroidectomy on quality of life and neuropsychological symptoms in primary hyperparathyroidism. World J Surg 2007;31:1202-1209.Weber T., Keller M., Hense I. et al. Effect of parathyroidectomy on quality of life and neuropsychological symptoms in primary hyperparathyroidism. World J Surg 2007;31:1202-1209.Brandi M.L., Gagel R.F., Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:12:5658-5671.Brandi M.L., Gagel R.F., Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:12:5658-5671.Uchino S., Noguchi S., Sato M. et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 2000;60:5553-5557.Uchino S., Noguchi S., Sato M. et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 2000;60:5553-5557.Melton L.J. Mayo Clinic, Rochester, Minnesota, USA. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Int Med 1997;126:6:433-440.Melton L.J. Mayo Clinic, Rochester, Minnesota, USA. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Int Med 1997;126:6:433-440.Vestergaard P., Mosekilde L. Incidence of primary hyperparathyroidism, frequency of surgical interventions and ortality based on the data from the National Patient Registry. Ugeskr Laeger 2004;166:41-45.Vestergaard P., Mosekilde L. Incidence of primary hyperparathyroidism, frequency of surgical interventions and ortality based on the data from the National Patient Registry. Ugeskr Laeger 2004;166:41-45.De Geronimo S., Romagnoli E., Diacinti D.et al. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol 2006;155:3:415-420.De Geronimo S., Romagnoli E., Diacinti D.et al. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol 2006;155:3:415-420.Asgharian B., Turner M.L., Gibril F. et al. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 2004;89:11:5328-5336.Asgharian B., Turner M.L., Gibril F. et al. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 2004;89:11:5328-5336.Geerdink E.A., Van der Luijt R.B., Lips C.J. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 2003;149:6:577-582.Geerdink E.A., Van der Luijt R.B., Lips C.J. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 2003;149:6:577-582.Ikeo Y., Sakurai A., Hashizume K. Characterization of the MEN1 gene product, menin, by site-specific polyclonal antibodies. Jpn J Cancer Res 1999;90:10:1088-1095.Ikeo Y., Sakurai A., Hashizume K. Characterization of the MEN1 gene product, menin, by site-specific polyclonal antibodies. Jpn J Cancer Res 1999;90:10:1088-1095.Piecha G., Chudek J., Wiecek A. Multiple Endocrine Neoplasia type 1. Eur J Int Med 2008;19:2:99-103.Piecha G., Chudek J., Wiecek A. Multiple Endocrine Neoplasia type 1. Eur J Int Med 2008;19:2:99-103.Eller-Vainicher C., Chiodini I., Battista C. et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 2009;24:8:1404-1410.Eller-Vainicher C., Chiodini I., Battista C. et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 2009;24:8:1404-1410.Trump D., Farren B., Wooding C. et al. Clinical studies of multiple endocrine neoplasia type 1 (MENI). Q J Med 1996;89:653-669.Trump D., Farren B., Wooding C. et al. Clinical studies of multiple endocrine neoplasia type 1 (MENI). Q J Med 1996;89:653-669.Makras P., Papapoulos S.E. Medical treatment of hypercalcaemia Hormones (Athens). 2009;8:2:83-95.Makras P., Papapoulos S.E. Medical treatment of hypercalcaemia Hormones (Athens). 2009;8:2:83-95.Palmér M., Jakobsson S., Akerström G., Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Inv 1988;18:1:39-46.Palmér M., Jakobsson S., Akerström G., Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Inv 1988;18:1:39-46.

The authors declare that there are no conflicts of interest present.